Abstract: The present application discloses a method for producing peripheral blood stem cells with improved angiogenic properties through EPO or APS priming, and a use thereof. The cells produced according to the method of the present application induce angiogenesis, and thus can be effectively used for the regeneration of, or recovery from, various diseases requiring facilitation of angiogenesis, such as ischemic diseases occurring in the muscle, brain, heart, kidney, or large intestine, e.g. tissue damage, cerebral infarction, stroke, reperfusion injury, myocardial infarction, congestive heart failure, peripheral vascular obstruction, cardiac hypertrophy, low heart contraction, low heart dilatation, maladaptive cardiomegaly, systolic heart failure, diastolic heart failure, hypertensive heart failure, artery or mitral valve diseases, heart blood vessels with pulmonary valve diseases, or ischemic heart blood vessels, caused by ischemia.

Abstract: The present application discloses a method for producing peripheral blood stem cells with improved angiogenic properties through EPO or APS priming, and a use thereof. The cells produced according to the method of the present application induce angiogenesis, and thus can be effectively used for the regeneration of, or recovery from, various diseases requiring facilitation of angiogenesis, such as ischemic diseases occurring in the muscle, brain, heart, kidney, or large intestine, e.g. tissue damage, cerebral infarction, stroke, reperfusion injury, myocardial infarction, congestive heart failure, peripheral vascular obstruction, cardiac hypertrophy, low heart contraction, low heart dilatation, maladaptive cardiomegaly, systolic heart failure, diastolic heart failure, hypertensive heart failure, artery or mitral valve diseases, heart blood vessels with pulmonary valve diseases, or ischemic heart blood vessels, caused by ischemia.

Abstract: There are provided a pharmaceutical composition for treating immune-related diseases, a pharmaceutical composition for treating ischemic diseases, a pharmaceutical composition for promoting lymphangiogenesis, a pharmaceutical composition for treating neurological diseases, a pharmaceutical composition for treating metabolic diseases, and the like, which contain blood-born hematospheres, and more specifically, may differentiate into inflammatory mononuclear cells, vascular endothelial cells, vascular smooth muscle cells, lymphatic vessel adult stem cells and progenitor cells, neural progenitor cells and nerve cells, insulin secreting cells, and the like by effective 3D culturing using blood mononuclear cells. Therefore, the present invention is expected to be used for development of a cell therapeutic agent for various types of diseases.

Abstract: An apparatus and a method of realizing an antenna matching in accordance with a user's body effect and a state of a mobile device are provided. The method includes determining a state of the mobile device on a basis of a call mode and at least one of whether an external device is connected to the mobile device, whether a receiver is being used, whether a speaker is being used, and whether a proximity sensor is activated, determining an optimal Tunable Matching Network (TMN) circuit adjustment value in accordance with the determined state, and performing the antenna matching in accordance with the optimal TMN circuit adjustment value.

Abstract: An apparatus and a method of realizing an antenna matching in accordance with a user's body effect and a state of a mobile device are provided. The method includes determining a state of the mobile device on a basis of a call mode and at least one of whether an external device is connected to the mobile device, whether a receiver is being used, whether a speaker is being used, and whether a proximity sensor is activated, determining an optimal Tunable Matching Network (TMN) circuit adjustment value in accordance with the determined state, and performing the antenna matching in accordance with the optimal TMN circuit adjustment value.